274 related articles for article (PubMed ID: 29496311)
21. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
[TBL] [Abstract][Full Text] [Related]
22. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
24. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
[TBL] [Abstract][Full Text] [Related]
25. [Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation].
Zhang XD; Liu DR
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 50(4):640-644. PubMed ID: 30122764
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
27. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
[TBL] [Abstract][Full Text] [Related]
28. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
29. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Saruwatari K; Ikemura S; Sekihara K; Kuwata T; Fujii S; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ochiai A; Kohrogi H; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2016 Jan; 91():7-14. PubMed ID: 26711928
[TBL] [Abstract][Full Text] [Related]
30. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
[TBL] [Abstract][Full Text] [Related]
31. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification.
Shim HS; Lee DH; Park EJ; Kim SH
Arch Pathol Lab Med; 2011 Oct; 135(10):1329-34. PubMed ID: 21970488
[TBL] [Abstract][Full Text] [Related]
32. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
33. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
Chao L; Yi-Sheng H; Yu C; Li-Xu Y; Xin-Lan L; Dong-Lan L; Jie C; Yi-Lon W; Hui LY
Lung Cancer; 2014 Nov; 86(2):164-9. PubMed ID: 25236981
[TBL] [Abstract][Full Text] [Related]
34. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
35. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
36. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
Fujimoto D; Tomii K; Otoshi T; Kawamura T; Tamai K; Takeshita J; Tanaka K; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Hata A; Tachikawa R; Otsuka K; Hamakawa H; Katakami N; Takahashi Y; Imai Y
Lung Cancer; 2013 May; 80(2):159-64. PubMed ID: 23419507
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]